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ABBREVIATIONS
1. AFB Acid fast bacilli
2. aPTT Activated partial thromboplastin time
3. ATS American Thoracic Society
4. BTS British thoracic society
5. BAL Broncho alveolar lavage
6. CAP Community acquired pneumonia
7. COP Cryptogenic organizing pneumonia
8. COPD Chronic obstructive Pulmonary disease
9. CBNAAT Catridge based nucleic acid amplification test
10. CT Computed tomography
11. ELISA Enzyme linked immunosorbent assay
12. FOB Fiberoptic bronchoscopy
13. FNAC Fine needle aspiration cytology
14. HIV Human immunodeficiency virus
15. IDSA Infectious disease society of America
16. LRI Lower respiratory infection
17. LPA Line probe assay
18. MGIT Microscopic growth indicator tube
19. MTB Mycobacterium tuberculosis
20. NRP Non resolving pneumonia
21. TBLB Transbronchial lung biopsy
22. TBNA Transbronchial needle aspiration
23. PT Partial thromboplastin time
24. PCR Polymerase chain reaction
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1INTRODUCTION
Pneumonia is defined as inflammation of the pulmonary parenchyma
caused by an infectious agent (1).. Inappropriate or delayed treatment leads to
morbidity, mortality and drug resistance in significant number of population.
Non resolving pneumonia is one of the common clinical problem.
Infection with drug resistant organisms, Misdiagnosis of pathogen, presence
of co morbid conditions, development of complications, non infective
etiology are some reasons for non resolution. Selection of patients and
appropriate timing of further evaluation can be challenging. There is no
uniform diagnostic or treatment approach for patients with non resolving
pneumonia.
Along with other routine investigations, Fiberoptic bronchoscopy
(FOB), Computed Tomography scan of the thorax and CT-guided fine
needle aspiration cytology (FNAC) may be helpful in the evaluation of non-
resolving or slowly resolving pneumonia. FOB is one of the most useful
procedure in the evaluation  of patients with non resolving pneumonia.
This study is to establish the etiology of non resolving pneumonia by
using FOB.
2REVIEW OF LITERATURE:
Pneumonia:
Pneumonia is defined as inflammation of the pulmonary
parenchyma caused by an infectious agent (1).Pneumonitis  reflects
inflammation due to both infectious and non infectious cause. Various
terminologies are used to describe various forms of pneumonia which
reflects the possible etiology .These include aspiration pneumonia,
community acquired pneumonia, nosocomial pneumonia,ventilator
associated pneumonia etc.
Pneumonia is one of the leading cause for mortality and morbidity
worldwide. Inappropriate  or delayed treatment leads to mortality,morbidity
and drug resistance in significant number of population. Community
acquired pneumonia (CAP) is one of the common clinical problem
characterized by cough, fever, chills, fatigue, dyspnoea, rigors, and pleuritic
chest pain—with or without new infiltrate on chest radiography. Majority
of patients it responds well with initial empirical antibiotics. Only few
patients respond poorly, resulting in non resolving pneumonia or death.
Despite advance in medical management, the mortality rate remains 5 to 15
% (2) Pneumococcus and multiorganism infection are the most common
causes which require treatment in an intensive care unit.
3ETIOLOGY:
Streptococcus pneumoniae is the most common cause of community
acquired pneumonia(CAP).Hemophilus influenza and Moraxella catarrhalis,
are more common in patients who have underlying chronic lung disease like
COPD. Staphylococcus aureus, occurs more commonly during an influenza
outbreak.   Individuals on long term steroids, or alcoholics,  frequent
exposure to antibiotic and those with severe underlying bronchopulmonary
disease are at risk of infection with Enterobacteriaceae species and P.
aeruginosa. Less common causes of pneumonia include Streptococcus
pyogenes, Neisseria meningitidis, Pasteurella multocida and H. influenzae.
The “atypical” organisms, which include Mycoplasma pneumoniae,
Chlymadia pneumoniae, Legionella are other causes. These are more
prevalent among outpatients.
Viral causes of CAP in Adults : RSV, adenovirus, and parainfluenza virus,
Human meta pneumovirus, herpes simplex virus, Varicella-zoster virus,
SARS-associated coronavirus, and measles virus. Viral etiology(18%)
identified as a cause of community acquired pneumonia in a recent study
among immunocompetent adult patients .Respiratory Syncytial Virus was
the most common pathogen identified in this study . They concluded viral
pneumonia also common among outpatients(3).
Other etiologic agents rarely idenified are:
4 Chlamydia psittaci [psittacosis],Coxiella burnetti[Q fever],Francisella
tularemia[tularemia],Bordetella pertussis[whooping cough].
 Fungai- Histoplasma  capsulatum, Cryptococcus neoformans, Blastomyces
hominis, Coccidioides immitis.
They are less common and only 2 to 3 % of total.
Anerobes -common cause of aspiration pneumonia.
Risk Factors:
Causative organisms from the upper airways or less commonly from
hematogenous spread or direct spread from a contiguous focus find their way
to lung parenchyma. Conditions such as altered sensorium, stroke facilitate
aspiration of contents into lungs. Loss of upper airway reflexes such as
cough, impairment of local defense mechanism such as mucosal blanket
which is lost due smoking and irritants ,factors that destroy alveolar
epithelium such as tobacco smoking, bronchial metaplasia or neoplasia,
pulmonary edema and congenital causes such primary ciliary dyskinesia
contribute to occurrence of pneumonia
PATHOGENESIS:
The host defense system  include intact mucosal epithelium, ciliary
mechanism, white blood cells, alveolar macrophages ,inflammatory
mediators like interleukins, chemokines etc. Microrganisms commonly
enter the respiratory tract but  immune  defense mechanisms, help in clearing
5them. Pneumonia  occurs when there is impaired  host defense ,or  as a
result of infection with virulent organisms, a large “dose” of bacteria.
Microbes  gain access to  the lung by any  of  the following routes:
 Micro aspiration from the upper respiratory tract
 Droplet infection from infected person
 Spread from contiguous infected sites
 Hematogenous spread
Once the pathogen or agent enters the bronchi and bronchioles, it
firmly fixes with the wall and causes cascade of inflammation in the host
body. There are two main types of acute pneumonia : bronchopneumonia
(with lobular topography) and lobar pneumonia (lobar topography). Lobar
pneumonia causes  exudative inflammation of an entire pulmonary lobe. If
not treated, lobar pneumonia evolves in four stages.
1.exudative phase2.red hepatizaton3.gray hepatization 4.resolution
Common to all stages is the enlargement of the affected lobe with loss of its
spongy appearance.
EVALUATION OF PATIENTS WITH SUSPECTED PNEUMONIA:
a)Detailed clinical history which includes age, onset of symptoms, resident
area, recent travel, prior hospital admission, antimicrobial treatment, co
morbid conditions can give some clue to etiology.
6b)General examination and respiratory system examination is vital.Physical
examination may not be reliable in immuno compromised individual.
c)Investigations:
 complete blood count,C reactive protein,Blood culture:polymorpho
leucocytosis is observed in bacterial etiology.
 Chest X ray:Pneumonia may present with various radiological patterns
which includes  consolidation,  bronchopneumonia,  miliary pattern,
nodules, abscess, effusion, interstitial pattern, lymph adenopathy
 Noninvasive microbiological testing which includes sputum examination
for cytology, Gram stain, KOH mount, Ziehl Neelson or flurochrome
stain,various special stain to the specific organisms,sputum for culture and
sensitivity are used.
 Bacterial and viral antigen detection by using ELISA ,latex particle
agglutination, PCR . For example, studies show  Steptococcus pneumonia is
better identified by molecular and urinary test rather than sputum culture
examination.
To identify M.TB CBNAAT,LPA,MGIT like rapid diagnostic methods
can be used. In patients who show poor response to  treatment, additional
investigations including invasive procedures are necessary to identify the
cause. These include trans tracheal aspiration, FOB guided
biopsy/BAL/TBNA open lung biopsy etc.
7TREATMENT:
According to 2007 IDSA guidelines, initial treatment for most of the
patients remains empirical.Selection of antibiotics is based on likely
pathogen and knowledge of local susceptibility patterns. We should consider
individual risk factor for each of the patients and must treat accordingly.
For sick patients admitted, the first antibiotic dose should be administered
as early as possible. Patients with CAP should be treated for a minimum of
5 days , should be afebrile for 48–72 h, and should have no more than 1
CAP-associated sign of clinical instability  before discontinuation of
therapy.A longer duration of therapy may be needed if initial therapy was
not active against the identified pathogen  or if it was complicated by
extrapulmonary infection.
 Out patients with no risk factors a macrolide or doxycyline is
recommended.
 Outpatients with co morbidities such as heart, lung, liver
or renal disease; diabetes mellitus; alcoholism; malignancies;asplenia;
immunosuppressing conditions or use of immunosuppressing drugs, a
respiratory fluoroquinolone or combination of  Beta lactam antibiotic with
macrolide  is recommended.
8 In areas with a high rate of infection with high-level (MIC _16
mg/mL) macrolide-resistant Streptococcus pneumoniae use of
alternative drugs is recommended.
 Hospitalised patients who are stable can be treated with either
respiratory fluoroquinolones or combination of β- lactam with
macrolides.
Inpatients requiring  intensive care:  β-lactam with azithromycin or
a respiratory fluoroquinolone (strong recommendation) (for
penicillin-allergic patients, a respiratory fluoroquinolone and
aztreonam are recommended)
Special concerns:
If Pseudomonas infection  is suspected, An  antipseudomonal β-lactam
(Piperacillin tazobactam,cefepime, imipenem, or meropenem) plus either
ciprofloxacin or levofloxacin  should be used.Other options are anti
Pseudomonal β-lactam plus an aminoglycoside and azithromycin Or The
above b-lactam plus an aminoglycoside and an antipneumococcal
fluoroquinolone (for penicillin-allergic patients, substitute aztreonam for
above b-lactam)
If MRSA is a consideration,  vancomycin or linezolid should be added.
9NON RESOLVING PNEUMONIA:
Non resolving pneumonia is one of the common clinical problems
encountered. The problems may range from simple delay in recovery to life-
threatening progressive pneumonia.
Definition of non resolving pneumonia :
Defining non resolving pneumonia is difficult, because of lack of a clear
cut and validated definition in the literature. In 1943, the term unresolved
organizing or protracted pneumonia was first described by  Amberson(5).
Non resolving pneumonia is a clinical syndrome in which focal infiltrates
begin with some clinical association of acute inflammation and despite
minimum of 10 days antibiotics patient either don't improve or worsen or
radiographic opacities fail to resolve within 12 weeks(6) .
According to IDSA/ATS 2007 guidelines, non resolving or slow-
resolving pneumonia refers to patients who present with persistence of
pulmonary infiltrates more than 30 days duration after initial pneumonia-
like syndrome.
Kirtland and Winterbauer defined non resolving pneumonia is less
than complete clearance of radiological infiltrates in 4 weeks or less than
50% clearance in chest infiltrates in patients who defervesed and improved
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symptomatically or non resolution of radiological infiltrates in an expected
period of time based on initial diagnosis and at least 10 days of antibiotics(7).
NORMAL VERSUS DELAYED RESOLUTION:
Resolution of pneumonia is not defined easily and it depends upon the
underlying etiology. Clinical recovery of the patients occur earlier when
compared to radiological resolution. Radiological resolution can take up to
six weeks. Microbiological resolution occurs with appropriate treatment.
After treatment, inflammation of lung parenchyma decreases and patients
improve clinically(8,9).
Fig(1):  Course of recovery in community acquired pneumonia
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Empirical treatment is mainstay of  treatment in CAP but studies show
6 to 15 % of inpatients are not cured by initial treatment(10,11).At the same
time, treatment failures among outpatients unit is so far not well studied. The
overall mortality was around 49% in hospitalised patients with severe CAP
who were not responding to the treatment(11) . In another study the mortality
rate was 27% (10).
According to the IDSA 2007 guidelines, treatment failure in CAP is
classified systematically in the following ways. The first entity is progressive
pneumonia or actual clinical deterioration, with acute respiratory failure
requiring ventilatory support and/or septic shock, usually occurring within
the first three days of hospital admission. The second pattern is that of
persistent  pneumonia which was defined as absence of or delay in achieving
clinical stability, using the Halm’s criteria.. The Infectious Diseases Society
of America/ American Thoracic Society (IDSA/ATS) 2007 guidelines
recommend the use of Halm’s criteria to define clinical stability. These
clinical criteria are reliable.They are applicable in  various healthcare
systems .
Halm's criteria consist of seven variables: 1.Temperature ≤37.8 °C,
2.Heart rate ≤100 beats/minute, 3.Respiratory rate ≤24 breaths/minute,
4.Systolic blood pressure ≥90 mmHg, 5.SPO2 ≥90%, or pao2 ≥60 mmHg
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6.normal mental status 7. normal oral intake(12). 2001 ATS guidelines
mentioned  clinical stability, which consists of  only four criteria.
1. Improvement in symptoms(cough and dyspnoea),2. afebrile (temperature
<37.8 °C) for more than 8 hours, 3.normalisation of  white blood cell count
by 10% from the previous day 4.adequate oral intake. Minimum duration to
achieve this criteria is 3 days.but in 1/4 th of patients required more than 6
days.
The  final entity is non resolving or slow-resolving pneumonia used
to describe patients with persistence of pulmonary infiltrates more than 30
days duration after initial pneumonia-like syndrome(13). Around   20% of
these patients have diseases other than CAP when carefully evaluated(14).
Most of the time,  normal resolution of pneumonia  mainly correlates
with radiological resolution. Persistance of radiological abnormalities with
improvement in clinical status is defined as slow resolution(15) .
Complete radioglogical clearing occurs by one to three months in
nonbacteremic cases and three to five months in bacteremic cases. Residual
radiographic abnormalities are rare in nonbacteremic cases but are present
in up to 35 percent of bacteremic cases(16).
Using systematic  approach, which include routine investigations
with appropriate invasive procedures, , specific etiology was acheived in
73% cases ,in a series of patients  with non resolving  pneumonia (17) .
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Factors affecting resolution of pneumonia are:
a) development of complications
b) infection with drug resistant organisms
c) misdiagnosis of pathogen
d) presence of comorbid conditions
e) non infective etiology
a) Complications:
Infectious complications which include empyema, complicated
parapneumonic effusion, and lung abscess. Sequestered foci of infection can
prevent adequate concentrations of antibiotics to reach the particular site and
prevent resolution
b) Virulence and drug resistance:
Streptococcus pneumoniae is the most common cause of community
acquired pneumonia and also responsible for majority of non resolving
pneumonia especially in patients with comorbidities.In pneumococcal
pneumonia, clinical symptoms subsided in majority of patients within 2 to 3
days of appropriate  treatment. Around 6 % of patients remain febrile beyond
20 days(18). In around 20 to 30 % of patients the radiological resolution was
slower. In case of legionella infection initial worsening of radiological
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changes followed by slow resolution begin only after 2 to 3 weeks. Around
50 % of infected patients will show radiological resolution by 10 weeks.
Residual fibrosis was noted in one fourth of patients. In case of Mycoplasma
pneumoniae rapid resolution is a rule.40% of patients will show complete
resolution at 4 weeks and 90% of patients at 8 weeks.
Like Mycoplasma,Chlamydia pneumonia infection is moreover
milder form of disease.50% of radiological changes resolve within 4
weeks.In 20% of patients it may take 9weeks.Residual abnormalities are
seen in 20 to 30%..After the introduction of conjugate vaccine, the incidence
of Hemophilus infection has drastically reduced in children worldwide.In
adults the course of Hemophilus disease not well studied. Available reports
show slow resolution and prolonged hospitalization in adults with
Hemophilus influenza pneumonia.
Apart from this ,resistant organisms like MRSA,MDR TB, multidrug
resistant gram negative bacilli, pencillinase resistant Streptococcus
pneumonia are responsible for delay in resolution.
c) Misdiagnosis of organism:
Tuberculosis is one of the most common etiology for non resolving
pneumonia. In atypical presentation, sputum  examination is often less
reliable and need more invasive procedure to detect Mycobacterium. Fungal
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infections like Histoplasmosis, Coccidioidomycosis, Blastomycosis,
Mucormycosis, Cryptococcus,
Aspergillus infection and Nocardia, Actinomycosis like organisms are also
responsible for non resolving pneumonia. Studies show Aspergillus may
mimic as bacterial pneumonia and are treated with multiple antibiotics
before the diagnosis is established(19).
d) Comorbid factors:
Associated co morbid conditions delay the resolution of pneumonia.
Only 20 o 30 % of patients with comorbid conditions will show radiological
resolution by 4 weeks(20). Extremes of age will show delay in resolution. 30%
of patients who were older than 50 years  will show slower radiological
resolution.
e) Non infective cause:
Noninfectious causes are responsible for non resolution of
pneumonia in 20 % of patients . In a study performed by Arancibia et al, in
patients   hospitalised for CAP, 19 patients had progressive pneumonia and
30 had non resolving pneumonia. Out of this, around  65% cases were  due
to infections . Persistance of primary infection was noted in 23 patients, 11
had developed a nosocomial infection, and non-infectious disorders like
16
neoplasm, foreign body, interstitial lung disease were present in 9
patients(17).
i) Neoplasms :
Primary  Lung cancer or metastasis are responsible for non
resolving pneumonia .The possible mechanisms are endobronchial
obstruction  or extrinsic compession which mimic pneumonia, secondary
postobstructive pneumonia or abscess, or by mimicking an infiltrative
process. Bronchogenic carcinoma and carcinoid tumors are the most
common cause of endobronchial obstruction leading to pneumonia.
Bronchoalveolar cell carcinoma and lymphoma are the most common causes
of an alveolar infiltrate mimicking pneumonia. The frequency of
endobronchial carcinoma as a cause of nonresolving pneumonia is Low,
ranging from 0 to 8 percent in most series(21).Bronchoscopy, CT guided
biopsy etc. are needed to diagnose malignancy.
ii) Inflammatory disorders
Cryptogenic organising pneumonia, diffuse alveolar damage, alveolar
haemorrhage, eosinophilic pneumonia, hypersensitivity pneumonitis,
vasculitis lipoid pneumonitis, pulmonary alveolar proteinosis, acute
interstitial pneumonia ,connective disease disorders may mimic pneumonia
.
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iii) Drugs
Drug induced lung disease can be confused with infectious
pneumonia. Examples include Amiodarone, Bleomycin, Methotrexate,
Nitrofurantoin. Amiodarone toxicity is an important mimic of NRP and can
present as focal alveolar infiltrates.
There is no clear guidelines regarding appropriate antimicrobial
therapy for non responding pneumonia .  Majority of cases of non resolution
are due to the severity of disease at presentation, associated co morbid
factors. For severe  pneumococcal pneumonia, combination therapy was
found to be useful(22). In case of NRP, rather than  using multiple broad
spectrum antibiotic course, other etiologies should be considered and
proceeded with necessary investigations This will help the patients to get
appropriate treatment in  appropriate time which in turn will reduce
morbidity and mortality.
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Fig:2 APPROACH  TO  NON RESOLVING  PNEUMONIA
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BRONCHOSCOPY
The ease and safe access to visualise bronchial tree has been a long
standing desire . After various evolution, today’s flexible bronchoscope
utilises modern technology for better differentiation and contrast
enhancement.
Bronchoscopy is a valuable diagnostic and therapeutic tool in
Pulmonary Medicine. It plays an important role in the diagnosis of non
resolving pneumonia.
HISTORY:
Gustavkillian is considered as the father of modern bronchoscopy.
Chevalier Jackson developed a rigid esophagoscope . Derivatives of this
device are now called rigid bronchoscopes.  Shigeto Ikeda , a thoracic
surgeon, developed flexible fiberoptic bronchoscope in the year 1968, which
is now known as  the year of “second revolution” in bronchoscopy(23)
Andersen was the first to perform bronchoscopic transbronchial lung biopsy
(TBLB) via the rigid bronchoscope in 1965. In 1958, Eduardo Schieppati
originally proposed transbronchial needle aspiration biopsy (TBNA) (24).
Inspired by the initial experiences of Oho and his colleagues(16) , Ko-Pen
Wang (1978) published the first report on the successful bronchoscopic
needle aspiration biopsy of paratracheal tumors through a flexible
bronchoscope.
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BRIEF REVIEW OF FLEXIBLE BRONCHOSCOPY DESIGN
The parts of FOB are eye piece, suction valve, angulation knob,
working channel, insertion tube, light guide connector (fig:3.)
Fig 3:Parts  of  Flexible Bronchoscopy.
Bronchoscope is designed   in such a way to accommodate adequate
number of glass fibres. This helps in  transmitting light into the lumen and
transport image from the distal end of the scope to the eyepiece.
The proximal tip of the bronchoscope can be angulated by a lever
which is located at the control section ( the central part of the scope). The
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bronchoscope can be bent only in two directions 180°and 130°. The
imaging fibre bundle in flexible fibreoptic bronchoscope is an important
component which determines the quality of image.  Clearer the image, better
is the chance of diagnosis so that therapeutic  options can be  planned
accordingly.  Each single fibre has the same dimension which is accurate .It
is positioned at similar position at both ends of the fibre bundle. If this is not
achieved, artefacts impair the the quality of image.(Figure 4)
Fig 4 :various internal parts of  FOB
22
There are  various channel ports in the bronchoscope.
a) The suction valve in control section is used for aspiration of mucus. It is
connected to an external suction apparatus . Using this valve, suction can be
done by the physician .
b) The  working channel or instrument channel port is located bit deep at
the lower part of the control section.(Figure 3). Endotherapy instruments can
be inserted into the bronchoscope using this port to reach the site of interest..
e.g. to guide biopsy forceps and to take sample for further investigation.  It
is also called biopsy channel. In order to save space, the instrument channel
is positioned to join the suction channel at the lower part of the control
section.
TABLE 1: SPECIFICATIONS OF FLEXIBLE BRONCHOSCOPE
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Endobronchial ultrasound (EBUS) , Navigation bronchoscopy
(NB), Ultrathin bronchoscopes(To visualise 6th to 8th generation bronchi in
adults and helps to detect more peripheral lesions(26)), Autofluorescence
bronchoscopy ( To detect central intraepithelial moderate or severe
dysplasia) are advanced technique used nowadays for diagnostic purpose.
Bronchoscopy can be used both for diagnostic and therapeutic
purposes.
Diagnostic Uses: Following procedures used to obtain diagnostic material.
1.Bronchoalveolar lavage(BAL)
2.Bronchial wash
3.Brushing
4.Transbronchial or (TBLB)
5.Endobronchial lung biopsy. (EBB)
6.Transbronchial needle aspiration.(TBNA)
Therapeutic Uses: Following  therapeutic procedures  can be done.
 Balloon dilatation
 Argon plasma coagulation
 Laser Electrocautery
 Brachytherapy etc.
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British Thoracic society (2001) recommends the following guidelines for
bronchoscopy.
BEFORE BRONCHOSCOPY:
 Verbal and informed consent should be obtained before  the procedure
 Solid diet can be allowed upto 4 hours prior to procedure
 Liquid intake upto 2 hours before procedure
 Prophylactic antibiotics should be given before bronchoscopy to patients
with asplenia,  prosthetic heartvalve, or previous history of endocarditis.
 FOB should be avoided for atleast 6 weeks following myocardial infarction.
 Atropine is not required routinely prior to the procedure.
 Oral anticoagulants should be stopped at least 3 days before. Or  their effect
be reversed with  vitamin K injection.
DURING BRONCHOSCOPY:
 During procedure, patients vitals should be monitored using pulse oximetry.
 SpO2 should be maintained atleast 90% .  Supplemental oxygen should be
administered if necessary.
 The maximal total dose of  lignocaine for topical anaesthesia should be
limited to 8.2 mg/kg in adults (approximately 29 ml of a 2% solution for a
70 kg patient). In old age patients or those with liver or cardiac diseases,
lesser dose should be used.
 Lignocaine gel(2%) is better compared to spray for nasal anaesthesia.
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 Equipments necessary for emergency resuscitation should be kept ready.
AFTER BRONCHOSCOPY:
 Oxygen supplementation may be required in patients, particularly those
with impaired lung function and  those who have been sedated.
 A chest radiograph should be taken  at least one hour after transbronchial
biopsy to exclude  air leak.
CLEANING AND DISINFECTION:
 Immersion time of 20 minutes is recommended for  bronchoscopes at the
beginning and end of a session and between patients.
 Longer immersion time of 60 minutes is recommended in known or
suspected atypical mycobacterial infections and in HIV positive individuals
with respiratory system complaints.  Mycobacterium avium intracellulare
and other atypical mycobacteria are more resistant to glutaraldehyde.
Patients with suspected tuberculosis should undergo bronchoscopy at the
end of the list.
PROCEDURE:
Figure 5 shows, step by step procedure of bronchoscopy. Gross
examination of upper respiratory tract, vocal cord movements,
tracheobrnchial tree followed by various  procedures can be done.
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MONITORING:
Patient should monitored for any fall in saturation and hemodynamic
instability. vitals which includes heart rate, oxygen saturation(>92%) ,blood
pressure, ecg monitoring are monitored throughout the procedure.
Intravenous access necesssary for all the patients. resuscitation equipments
and supplemental oxygen should be available.
All FOB procedures are performed using standard guidelines.
27
Fig 5:Bronchoscopy-step by step Approach.
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Gross examination of respiratory tract during the procedure can give
valuable information. Endobronchial tuberculosis, mass or mucus plug
occluding the lumen  are some of the causes of non resolving pneumonia
which can be diagnosed by gross examination of tracheobronchial tree.
Fig 6:Nodular lesion in lower trachea due to Endobronchial TB
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Fig 7:Tuberculous Granuloma occluding the anterior segment of Right
Upper Lobe.
Fig 8:Mucus plugging due to allergic Bronchopulmonary Aspergilosis.
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Fig 9:Irregular,narrowed lumen due to infiltrative malignant lesion
occluding right main bronchus.
Fig 10:Mass lesion totally occluding the left upper lobe
bronchus.
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BRONCHO ALVEOLAR LAVAGE:
Bronchoalveolar lavage(BAL) is a minimally invasive important
diagnostic tool in pulmonary  medicine(27,28). It is particularly useful in
patients with diffuse lung abnormalities. It is also called liquid lung biopsy.
BAL fluid contains both cellular and noncellular components of the
alveoli and epithelial surface of the lower respiratory tract. Components of
the BAL fluid represent the inflammatory and immune status of the lower
respiratory tract and the alveoli(29). BAL procedure is a better option when
compared to TBLB &TBNA in  patients who are  at risk of bleeding
TECHNIQUE:
Bronchoalveolar lavage is performed following general inspection of
the tracheobronchial tree and before biopsy or brushing(30). Middle lobe or
lingula is the preferred site for lavage in diffuse lung disease. In focal lesions,
the site with maximum radiographic changes is chosen.We should avoid
suction prior to the procedure. If suction is done before the procedure, the
suction channel should be cleaned thoroughly with saline.To avoid the
bacteriostatic effect of local anesthesia,we should limit  the  use of lignocaine
as much as posssible.
Bronchoscope is advanced until it reaches the wedge position .Good
wedge position means that the bronchoscope is advanced as far as possible
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without losing the view of lumen. Over wedging the scope will cause trauma
to patient and diminish fluid recovery. Poor wedge position leads  to fluid
leakage around the scope and will stimulate cough soon after instillation.
20 ml of  sterile normal saline is used at room temperature or warmed
to 37.c to decrease the cough and increase the cellular yield. Bubbling of fluid
via FOB  indicates  return of fluid from alveolar space.  Gentle suction is
used within the  range of 50 to 80 mm of Hg. We have to repeat the procedure
5 to 6 times with maximum amount of fluid 100 to 120 ml. According to
ATS guidelines,40 to 70 % of instilled fluid should be aspirated and sent
immediately to analysis.  The patient  should be observed for at least 1 hour
for any immediate complications following procedure. Protected broncho
alveolar lavage is another method to collect uncontaminated specimen from
lower airways.
Mini broncho alveolar lavage is another method which is used mainly
in ICU setup to avoid more invasive procedure in patients who are already
in respiratory compromise. It  is performed blindly,without  visualising
tracheobronchial tree.Small volume of sterile saline is injected, which is then
aspirated and sent for analysis. It is mainly useful  to detect etiology of
pneumonia in patients undergoing mechanical ventilation(31,32).
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BAL fluid sent is immediately for various analysis.
 cytology and cell count
 bacterial & fungal culture and sensitivity
 BAL fluid for AFB stain and CBNAAT
Normal BAL
The BAL fluid obtained from healthy, nonsmoking adults without
underlying lung disease is dominated by alveolar macrophages (>80%).
Normal content of BAL:
 Alveolar macrophages -80–90%
 Lymphocytes- 5–15%
 Polymorphonuclear neutrophils 1–3%
 Eosinophils-1%
 Mast cells-<1%
BAL Cytology:
The fluid is centrifuged and the concentrate is used to make smears,
thin layer preparations, or cell blocks. Cytology  of  BAL is useful in
identifying various type of malignancies, diffuse alveolar hemorrhage,
eosinophilic lung diseases and various forms of interstitial lung diseases .
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Fig 11 : BAL fluid cytology showing   Adenocarcinoma. It has
columnar cells with polarized nuclei and single prominent nucleoli
Fig 12 : BAL cytology  smear: squamous cell carcinoma. Picture
shows clusters of polygonal cells with eosinophilic cytoplasm and
hyper chromatic nuclei.
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By identifying the organisms in the BAL specimen by various staining
and culture methods we can diagnose Pneumocystis jiroveci,Toxoplasma
gondi,Strongyloides stercoralis,Cryptocoocus neoformans,Histoplama
capsulatum, Legionella pneumoniae, Infuenza virus(A & B),Respiratory
syncitial virus.
Fig 13:  BAL fluid GMS(gomori methenamine silver ) stain
showing round to cup shaped pneumocystis.
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Fig 14: BAL specimen showing AFB in fluorescence
staining.(0.1% Auramine stain)
DETECTION OF MYCOBACTERIUM TUBERCULOSIS:
BAL fluid subjected to fluorescence staining with 0.1% Auramine
solution  can detect Mycobacterium tuberculosis.  Recently, rapid diagnostic
method like gene Xpert/CBNAAT is used.
Nucleic acid amplification (NAA) test uses a disposable cartridge
with the Gene Xpert Instrument System . Mycobacterium tuberculosis
complex (MTBC) and  Rifampicin resistance  ( RNA polymerase beta
gene(rpoB) can be detected in less than 2 hours. Bronchial wash around  2-
5ml and Bronchial alveolar lavage (BAL) (minimum volume of 20 50 ml)
should be sent for gene xpert to detect M.TB .
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Fig 15:Various steps of gene Xpert plotted in the following diagram.
BAL analysis is a useful diagnostic tool in nonresolving pneumonia.
Quantitative analysis of  BAL which  show more than 104 CFU/ml is useful
to diagnose pneumonia .Sensitivity was around 22 to 93% and the specificity
was 45 to 100% depending upon the clinical condition of the patients. A
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study by Van der Eerden and colleagues revealed FOB  was additional
diagnostic value in in 49% of patients who were unable to raise sputum for
Gram stain and culture and in 52% of patients for whom treatment
failed(33).BAL fluid taken after starting antibiotic treatment may
significantly reduce the yield , but Feinsilver et al reported, 86% yield in
patients with nonresolving pneumonia who were already treated with
antibiotics(29).
In immunocompromised individuals the yield is higher, around
93%.The results of BAL have been shown to change disease management in
up to 84% of immunocompromised cases(35). The diagnostic yield of BAL
for peripheral cancerous lesions range from 4 to 68%(36).
According to ATS guidelines, following BAL no complications were
identified in upto 95% of patients.Transient fever was noticed in 2.5% of
patients.Transient pulmonary infiltrates are also described ,but  usually
subside within 24 hours. Their incidence increases with total amount of fluid
and number of segments lavaged. Persistant fever and  progressively
increasing pulmonary infiltrate  indicate postbronchoscopic pneumonia
warranting the need for antibiotic therapy(37).Transient
bronchospasm(<1%),transient hypoxia,transient fall in pulmonary function
tests are other complications.
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BRONCHIAL WASHINGS:
Bronchial washings is an easy procedure  useful to diagnose  mainly
airway diseases.
Procedure:
10 to 20 ml of sterile saline is instilled into the airways and then
aspirated immediately.The aspirated material is then subjected   for analysis.
The diagnostic yield of bronchial washings in various studies vary from 27
to 90% .The yield is highest for central lesions.
TRANSBRONCHIAL LUNG BIOPSY:
Biopsy of the lung was performed by open surgical methods until
1963, when Dr. Anderson performed bronchoscopic lung  biopsy with a rigid
bronchoscope.
In 1974, Levin et al, published their experience with transbronchial
biopsy using  flexible bronchoscopy. Various lung pathologies can be
diagnosed using transbronchial lung biopsy. It is mostly performed with
topical anaesthesia. This procedure not required hospitalisation .
Transbronchial biopsy is employed in the setting of neoplastic disease,
interstitial lung disease, pulmonary infection, unusual and unclear lung
disease, and lung transplantation.
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BEFORE PROCEDURE:
A detailed history, physical examination, Chest X-Ray, CT chest,
informed consent are essential before procedure. Lab tests include
 Prothrombin time (PT-INR)
 Activated partial thromboplastin time (aPTT)
 Renal functions tests-serum urea, creatinine
 Liver function tests  are necessary in special situations like patient on
anticoagulants, uremic patients.
TBLB can be done only when:
 PT-INR less than 1.5
 aPTT  less than 50 seconds.
 Platelet counts  more than 50,000 .
 Clopidogrel, should be stopped one week before procedure. Warfarin
should be withold 3 days before procedure. Unfractionated heparin should
be stopped before six hours . But aPTT should be monitored before the
procedure. For patients using low moleular weight heparin(LMWH),with
hold  at least 12 hours before the procedure. Patients using Aspirin or
NSAIDS can be allowed to continue their medication.
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Procedure:
After  the gross examination of tracheobronchial tree, TBLB is
performed. Advance the  scope until it reaches the diseased segmental
bronchus of interest. Then the cup shaped biopsy forceps should be passed
via the working channel of the FOB. It is advanced to the periphery of the
diseased region. Placing  the  forceps near, but not at the lung surface,
decreases the risk of pneumothorax. Next, the forceps is withdrawn
approximately 1 cm, jaws are opened and advanced slightly to obtain the
sample . The forceps is then advanced  to diseased area where resistance was
encountered, and the jaws are closed. In case the patient reports pain at this
point, the forceps is gently opened and withdrawn. Only the visceral pleura
is pain sensitive.The biopsy forceps is firmly retracted to obtain the sample
.This is then placed in formalin and sent for histopathologic evaluation.
Number of Biopsy Specimens
BTS  recommendation(38):
 4 to 6  biopsy samples for diffuse lung disease
 7 to 8 samples for focal lung disease
In patients with diffuse lung disease, single sample yield is around
53% and 33% of diagnosis were provide with second sampling. In case of
sarcoidosis stage (  2 and 3) 4 to 6  specimen will provide adequate diagnosis
but in stage 1 disease, additional biopsy specimens upto 10 is needed(39). In
a large study, the diagnostic yield from localized lesions increased was 23%
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with 1–3 specimens .But if we take 6–10 specimens,the yield increases to
73%.(40).
Specimen Handling
The specimens obtained from the procedure are placed in container
filled with 10 % formalin and sent for histo pathological examination.
Whenever infections are considered, biopsy material sent to the
microbiology lab in Ringer’s lactate. The quality of biopsy specimen is
difficult to asssess because the size of the tissue fragment is very tiny in the
range of 1 to 3 mm. In one study, they proposed that biopsy specimen
containing more than 20 alveoli may be considered adequate to diagnosis
infective etiology(41). But subsequent studies showed it is not reliable in all
cases, and many physicians still believe diagnostic yield from TBLB
depends more on the number of the specimens obtained rather than actual
number of alveoli in each biopsy specimen. In another study, they proposed
that tissue with alveoli were more likely to float in 10% formalin rather than
tissue without alveoli (float sign) but the practical value  is still unproven(42)
Pneumothorax and hemoptysis are the important complications but
occurs only less than 2 % of patients.
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Fig 16:    Transbronchial lung biopsy procedure.
Fig 17 :Histology section of lung biopsy showing Tuberculous
granuloma.
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Fig 18:HPE of lung biopsy showing Mucormycosis. It has irregular
branching aseptate  hyphae.
TBNA:
Transbronchoscopic needle aspiration (TBNA) by using rigid
bronchoscope was first reported by Schieppati in 1958. Since 1978
,fiberoptic bronchoscopy is used for trans bronchial needle aspiration.
TBNA is a useful technique for obtaining sample from mediastinal nodes.
Hilar lymph nodes, mediastinal mass lesions close to the airways also
sampled with this technique. It is a blind procedure. The diagnostic yield is
widely variable ranging from 15% to 83%. The yield mainly depends on the
size and location of the nodes and  operator’s experience.
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Fig 19: Transbronchial needle aspiration(TBNA) procedure
Fig 20: Cytology smear made from Aspirates.
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The needle used for TBNA should be retractable with size between 18
and 22 gauge, length  between 13 and 15 mm. Lymph nodes with clear
anatomic landmarks (Eg:right lower and left paratracheal mediastinal lymph
nodes , subcarinal lymph nodes and hilar lymph nodes)  can be adequately
sampled .(43)A recent meta-analysis reported a sensitivity of 78% (44).
Overall major complication rate is very less approximately 0.26%.
Complications include damage to the working channel of the bronchoscope,
fever, and minor bleeding from the puncture site(46).
BRONCHIAL BRUSH
Lesions not reachable by direct biopsy with a forceps can  be accessed
using  bronchial brush. This instrument contains a rigid central wire
surrounded by brushes of different size and shape. The brush can be moved
to and fro against the nearby tissue, by which samples can be obtained.
Minor trauma  can occur to the tissues due to  brush movement. The collected
sample specimens are used for cytological or microbiological analysis.
When bronchial brushing is combined  with endobronchial biopsy of central
lesions, the diagnostic yield of FOB increases between 79% and 96%.
Protected Specimen Brush:
This technique is used  to help to arrive at etiological diagnosis in
patients with suspected pneumonia. The brush is enclosed within a double
catheter sheath using which specimens are collected. The catheter is sealed
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at distal end by a wax plug. The plug can be removed easily before obtaining
the specimen. The catheter sheath and wax plug is to prevent contamination
of the brush with nasopharyngeal flora, that remain inside the working
channel of the bronchoscope.
Fig 21: Bronchial brushing procedure.
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Fig 22 : Brush cytology smear of small cell carcinoma  showing
tightly packed cells with well preserved powdery chromatin texture .
Fig 23: Bronchial brush cytology MUCORMYCOSIS:characteristic
branching, ribon like hyphal fragments without septa .
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A prospective observation study was conducted by Mohammed El
Shabrawy et al(47) in  Department of Chest medicine, Zagazig
University,Egypt from Sep 2013 to Feb 2015.A total of 135 patients with
NRP were included in the study.Patients were subjected to FOB and
BAL.Most common cause of NRP in their study was pyogenic infections
113 (83.7%) followed by malignancy in 18 (13.5%) and TB in 4
(2.9%)patients.BAL fluid cytology was positive in 33.3% of patients. TBLB
was positive in 55.5% , bronchial brush was positive in 16.6% of patients.
Among infections, Klebsiella pneumoniae was the most common organism
isolated in 29 (24.8%) patients followed by Pseudomonas (19.65%) and
Streptococcus pneumoniae (19.65%).Predominant site of involvement was
right upper lobe in 25.9% of patients. They reported diabetes mellitus was
most common co morbidity associated with non resolving pneumonia.
Bhupendra Kumar Jain et al(48) studied the role of FOB and CT guided
FNAC in diagnostic evaluation of non resolving pneumonia.Sixty five
consecutive patients with non resolving pneumonia admitted under
respiratory medicine unit were subjected to FOB.In patients where FOB
result was inconclusive,CT guided FNAC was done. The  most common
cause  for non resolution found in this study   was pyogenic bacterial
infections in 24(37%)patients ,followed by TB 19(29.2%), bronchogenic
carcinoma in 15(23%) patients and others.Among infections Streptococcus
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pneumoniae (50%)was the most common bacteria isolated Pseudomonas,
Klebsiella, Legionella, Aceitnobacter, Staphylococcus were isolated in rest
of  patients.  Squamous  cell variety  was the predominant carcinoma
detected in their study accounting for eight out of 15 malignancy cases.
Smoking, alcoholism, diabetes and bronchiectasis were significantly
associated with non resolution(p<0.5). Right upper lobe was the most
common site  involved in 25% patients. The overall diagnostic yield of  FOB
was 81%.In patients with inconclusive results from FOB, CT guided FNAC
was done. They concluded that FOB should be the first option in evaluating
NRP before CT guided FNAC.
Arunabha D Chaudhri et al,(49) conducted a prospective, observational
study in a tertiary care hospital involving 60 patients with non resolving
pneumonia .The efficacy of FOB and CT guided FNAC in arriving at
etiological diagnosis was studied. FOB was useful as a diagnostic tool in
85.7% of patients. Pyogenic infection (53.3%) was the most common
etiology followed by bronchogenic carcinoma in 26% and TB in 16.7% of
cases. Among infections, Klebsiella species were isolated in 13 cases
followed by Pseudomonas in 11 cases.Right lung particularly, right upper
lobe (25%)  was most commonly affected in NRP. Bronchogenic carcinoma
accounted for 16 cases, out of which predominant variety was squamous cell
carcinoma found in 10 cases followed by adenocarcinoma in 5 patients.
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Seven out of ten cases of squamous cell cancer was diagnosed by
bronchoscopy whereas all cases of adenocarcinoma was diagnosed by CT
guided FNAC . Multilobar or bilateral involvement was common in TB
patients (80%).CT guided FNAC was done in patients with inconclusive
results from FOB and in those who did not give consent for FOB. Combined
yield of FOB and CT guided FNAC was 98.33%.They concluded that  FOB
is a safe and very useful procedure and should be the first investigation of
choice before CT guided FNAC in evaluation of  NRP.CT guided FNAC is
a good procedure , especially for peripherally situated lesions.
Jayaprakash et al,(50) studied the etiology and clinical outcome of
NRP in tertiary care institute,Kerala. Study design was prospective
observation study.Out of 821 patients admitted with pneumonia,70 patients
with NRP were studied.Tuberculosis, 25 (35.7%) was the most common
etiology followed by malignancy in 19 (27.1% ) cases, infections with drug
resistant organism in 10 (14.3%) patients, Pneumocystis pneumonia in 7.1%
and BOOP in 5.7% of patients. Adenocarcinoma (42.1%) was the most
common among malignancies. Klebsiella species (60%) was the most
common pathogen among infections.Most common risk factor associated
with non resolution of pneumonia was smoking (60%).Other statistically
significant comorbities were diabetes mellitus,COPD and hypertension.
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A Prospective observation study was done by Batau Bhadke et al,(51)
in  2010 to study the utility of  FOB as a diagnostic tool in NRP.120 subjects
who satisfied inclusion criteria underwent FOB procedure.FOB was
diagnostic in 90(75%) patients. Bacterial pneumonia were found in
32(26.6%) patients,malignancy in 28(23.3%),pulmonary TB in
20(16.6%),fungal pneumonia in 6(5%) and foreign bodies in 4(3.33%)
patients. Streptococcus pneumoniae was the most bacterial etiology found in
16(50%) patients followed by Staphylococcus in 10(31.25%) and Klebsiella
in 6 (18.75%) patients.
Etiology and clinical profile of patients with NRP attending OPD,
chest hospital in Visakhapatnam was studied by Vipparthi Surya Kumari et
al,(52).A total of 32 patients with NRP were subjected to FOB, lung FNAC
and CT chest .TB (33.3% )followed by malignancy (30.3%) and infections
(16.6%) were the common etiologies for non resolution found in the study.
Squamous cell carcinoma and adenocarcinoma were the common
malignancies detected.Among infective cause, commonest organism
identified was Klebsiella (57.14%) followed by Pseudomonas (28.5%) and
E.coli (14.2%). Diabetes (23.3%) was the most common co-morbidity
associated with nonresolving pneumonia in the study followed by COPD
(20%), and Hypertension (16.6%).
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Nimit V Khara et al,(53) studied the diagnostic yield of FOB in 3
common lung conditions -pneumonia, TB and lung cancer. A total of  289
patients were included in study. The overall diagnostic yield of  FOB was
55.7% .The yield of FOB in diagnosing pulmonary TB was 37.7%.The
diagnostic yield was 48.7% and 68.5% in pneumonia and lung cancer
respectively. They  also  found FOB guided  BAL fluid analysis was very
useful in diagnosis and identification of the causative organism in patients
with non-resolving and hospital acquired pneumonia.
Amit J Asari et al,(54) conducted a retrospective observation study in a
tertiary care hospital, Ahamedabad. The primary objective of their study was
to study the yield of FOB in diagnosis of NRP.A total of 34 patients were
studied . Pyogenic infection was the most common etiology in 19
cases(55.88%) followed by bronchogenic carcinoma 8 cases (23.5%),TB in
6 cases(17.6%).Among infections, most frequent organism isolated was
Streptococcus pneumoniae in 8 patients (42.1%).Among malignancies, the
most common histological pattern was adenocarcinoma 4 (50%) followed
by squamous cell carcinoma 25%,small cell 12.5% and large cell carcinoma.
The importance of FOB with BAL in diagnosis of sputum smear negative
pulmonary TB was studied by Novin Nikbhash et al,(55) from Iran. A total
of 290 sputum smear negative TB patients between the years 2006 and 2012
were studied. All patients were subjected to FOB,BAL stain and culture.Out
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of 290 patients, BAL smear detected TB bacilli in 110 patients.Even in
patients in whom BAL smear was negative,BAL culture grew TB bacilli in
64 (35.5%) patients.Study concluded that FOB guided BAL is a rapid and
useful technique to establish definitive diagnosis in patients with sputum
smear  negative TB .
The yield of FOB with  BAL in association  with chest CT findings
and symptoms in immune compromised patients was studied by Kyle R
Brownback et al,(56). The study included a total of  133 subjects.The study
population included were those on immunosuppressant therapy,retro
positive individuals,neutropenics and  hematopoietic stem cell, organ
transplant recipients. The diagnostic yield of FOB was 52.7%. Infections
particularly viral were the most common etiology  found in
38(48.1%)patients followed by bacterial in 9(11%),invasive Aspergillosis in
14(17.7%) and Pneumocystis jiroveci in 6 (7.6%) patients. They concluded
that symptomatic patients were more likely to have diagnosis. Significantly
higher diagnostic yield was demonstrated in patients in whom, imaging
confirmed abnormalities within alveoli or airways .There was also better
diagnostic yield with BAL performed in lower lobes compared to middle
and upper lobes
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MATERIALS AND METHODS
STUDY TITLE
The present study ‘‘ROLE OF BRONCHOSCOPY  TO
DETERMINE   THE ETIOLOGY OF    NONRESOLVING
PNEUMONIA IN A TERTIARY CARE  INSTITUTE’’ was conducted
in Department of Thoracic Medicine, Tirunelveli Medical College,
Tirunelveli after obtaining approval from Tirunelveli Medical College
Institutional Ethical Committee(TIREC).
AIMS AND OBJECTIVES
 To find out the etiology  of non resolving pneumonia by using
Bronchoscopy .
 To study the role of bronchoscopy in non resolving pneumonia.
STUDY DESIGN:
Prospective observational study
STUDY PLACE:
Department of Thoracic Medicine, Tirunelveli medical College and
hospital
STUDY PERIOD:
From  June  2015 to August 2016
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STUDY POPULATION:
Adults (≥ 12 years)  admitted with non resolving pneumonia in
Thoracic medicine ward,Tirunelveli Medical College Hospital during the
study period
INCLUSION CRITERIA:
Patients who fulfill the criteria of non resolving pneumonia.(
patients who presented with pneumonia like syndrome and  the radiograph
has failed to resolve by 50% in 2 weeks, or completely in 4 weeks , or does
not show significant radiographic resolution after at least 10 days of
antibiotic therapy )
EXCLUSION CRITERIA:
1.Unwilling patients.
2.Known case of lung cancer
3.Known case of Sputum positive tuberculosis
4. Patients with  poor general condition, hemodynamic instability,
uncooperative patients.
5.Recent myocardial infarction
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METHODOLOGY:
After obtaining approval from ethical committee, a total of 68 patients
who fulfilled the study criteria were enrolled for the study. Name, age , sex,
residence, occupation of all patients were noted. Detailed clinical history
was taken. Duration of symptoms, prior history of ATT ,associated co
morbities like Diabetes, Hypertension, Coronary artery disease were
recorded. History of smoking, alcoholism was noted .Laboratory
investigations like complete blood count, Random blood sugar, Renal
function test, Liver function test  was done. Patients were tested for HIV,
hepatitis B, hepatitis C serology, Sputum for AFB( at least 3 samples) were
taken before procedure. Sputum for  Gram stain and culture, fungal stain and
culture ,sputum cytology for malignant cells were sent. Chest xray and CT
chest were taken in all patients . Further investigations like USG chest, USG
guided FNAC, cardiac evaluation, Serological test were done as needed.
Before the procedure, all patients were treated with empirical antibiotics at
least for 10 days according to the standard guidelines .
Bronchoscopy procedure, benefits, complications were explained  clearly
to the patients in their local language and consent(oral &written) was
obtained .Patients pulse rate, respirator rate ,blood pressure, oxygen
saturation were recorded before the procedure.  Olympus  BF-TE  2 model
conventional Fiberoptic bronchoscope was used for the study .It has 120
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degree field of view so that it  provides broader view. Tip has bending range
of 130 degree upward and 180 degree downwards. It has 2.8 mm diameter
and 600 mm length of working channel which allows better instrumentation.
For trans bronchial lung biopsy, Olympus FB -231 D type of standard oval
shaped biopsy forceps was used. It has 5 mm cup opening and a 115 cm of
working length. The Olympus BC-202D-3010 model bronchial brush with
covered sheath was used .Brush  was 10 mm in length and 3mm in outer
diameter Bristle diameter is 0.064mm in length.
During  Bronchoscopy, gross inspection of upper respiratory tract,
visualisation of  vocal cord movements ,tracheo bronchial tree inspection
followed by FOB guided procedures were done. Vitals and oxygen
saturation was monitored throughout the procedure. All procedures were
carried out according to standard guidelines and under universal precautions.
Samples collected were sent immediately to  lab.BAL fluid was
centrifuged at 1500 rpm for five minutes .Then smear stained with
hematoxylin and eosin stain  and then   cell count ,and cytology analysis
were made .BAL fluid was also sent for AFB, Gene Xpert, Gram stain and
culture, Fungal stain and culture. Samples obtained from bronchial brushings
were sent for cytology .Transbronchial lung biopsy specimen was preserved
in formalin and  sent for Histopathological examination. USG guided FNAC
was done in patients with inconclusive results from FOB procedure.
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After the procedure, patients were observed for at least one hour for any
complications like massive Hemoptysis or hypoxia. Post procedure chest
xray was taken  to rule out  Pneumothorax.
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RESULTS
SAMPLE SIZE:
Sixty eight(N = 68) Patients who fulfilled the study criteria were
included in the study.
GENDER DISTRIBUTION:
Of the 68 Patients included in the study, majority of the patients were
males 80%(n=54). Females were 20% (n= 14). [Fig 24]
MALE
80%
FEMALE
20%
Fig 24:Gender distribution
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AGE DISTRIBUTION:
3%(n=2) patients were between 15-20 years, 3%(n=2) were between 21-
30years, 15%(n=10) were between 31-40 years , 18% (n=12) were between
41-50 years, 25%(n=17) were between 51-60 years , 30%(n=21) were
between 61-70 years and 6% (n=4) were between 71-80 years age.[Fig 25]
In my study ,majority of patients were above 50 years of age.
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Fig 25 :AGE DISTRIBUTION
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CT-CHEST PATTERN
Computerised tomography of patients with non resolving pneumonia
showed  varied distribution. Majority of the patients with non resolving
pneumonia had lesions affecting right lower lobe 33% (n=23) followed by
lesion distributed in right upper lobe 26%(n=18).Non resolving
consolidation was seen in left lower lobe  in 14% (n=10) of  patients and left
upper lobe in 11%(n=8)of patients. Lingular segment was affected in
3%(n=2) of patients. Multi lobar distribution of consolidation were seen in
4%(n=3).[Fig 26]
TABLE 2: CT CHEST PATTERN IN MY STUDY.
CT CHEST
PATTERN
NO OF PATIENTS
(n – 68) PERCENTAGE
Right upper lobe 18 26.4%
Right middle lobe 4 5.88%
Right lower lobe 23 33.8%
Left upper lobe 8 11.7%
Lingular lobe 2 2.94%
Left lower lobe 10 14.7%
Multi lobar 3 4.41%
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FOB findings :
FOB showed various findings during gross inspection of
tracheobronchial tree. In 25%(n=17) of patients FOB study was normal.
Inflammed mucosa along with mucopurulent secretions was noted in
32%(n=22)  of patients. In  19% (n=13)of patients  visible endobronchial
mass lesion or nodular lesions  were seen. In 8%(n=) of patients mucoid
secretions and in few patients mucoid impaction were noticed and in
remaining 8% of patients,  bronchial segments  were irregular, inflammed
and narrowed.[Fig 27]
Even though 25 % of patients showed normal study during the
procedure,FOB guided  procedures revealed  the etiology in them.
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Fig 26:CT CHEST PATTERN
NO  OF  PATIENTS
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DIAGNOSTIC YIELD OF FOB:
Overall diagnostic  yield of FOB in my study was 94%(n=64).[Fig
28].In 3 out of 4 patients ,USG  guided FNAC was carried out which
revealed diagnosis. In remaining 1 patient diagnosis could not be made.
NORMAL STUDY
25%
MUCOID SECRETIONS
12%
MUCOPURULENT
SECRETIONS
32%
MASS/NODULAR
19%
NARROWED
&IRREGULAR LUMEN
12%
Fig 27:FOB Findings
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ETIOLOGY OF NONRESOLVING PNEUMONIA:
Majority of cases diagnosed in my study was infectious diseases
followed by malignancy. In  my study, infections is the  cause for non
resolution in 60.29% (n=41)  of patients . In 26.47% (n=18) of patients
malignancy was the etiology. Combined etiology was noted in
5.88%(n=4)and Interstitial pneumonitis was diagnosed in 1%(n=1).[Fig 29]
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Fig 28:YIELD OF FOB
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 Among the infectious causes,Gram negative pyogenic bacterial
infection was diagnosed in 41.1%(n=28).Tuberculosis was
diagnosed in 25% (n=17) and fungal infection - Mucormycosis
was diagnosed in 1%(n=1).[Fig 30]
 Klebsiella species is the predominant bacterial infection
identified followed by pseudomonas infection.
60%
26%
6%
2%
6%
Fig 29:ETIOLOGY OF  NRP
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TABLE 3: YIELD OF FOB IN NRP
Yield of FOB Frequency(n=68) Percentage
Infectious etiology
 Pyogenic
bacterial infection
 Tuberculosis
 Mucormycosis
26
14
1
60.29%
Malignancy 18 26.47%
Combined etiology 4 5.88%
Interstitial Pneumonitis 1 1.47%
Undiagnosed 4 5.88%
 Among the Malignancy, Squamous cell carcinoma was the predominant type
followed by Adenocarcinoma and small cell carcinoma.
 Dual etiology was diagnosed in 4 patients. Squamous cell carcinoma along
with tuberculosis was diagnosed in 2 patients. Another patient, Squamous
cell carcinoma combined with secondary bacterial (klebsiella species)
infection was diagnosed. In another patient tuberculosis and coagulase
negative staphylococcus aureus  was diagnosed.
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OVER ALL DIAGNOSIS
Various etiologies diagnosed in my study is summarised in table(4).[Fig
31]
TABLE 4:DIAGNOSIS OF NRP IN MY STUDY
DIAGNOSIS OF NRP NO OF PATIENTS
(n=68)
% PERCENTAGE
Klebsiella Species 17 25%
Pseudomonas Species 9 13%
Tuberculosis 14 20%
Squamous Cell
Carcinoma
13 19%
Adeno Carcinoma 4 6%
Small Cell Carcinoma 1 1%
Squamous Cell
Carcinoma & PTB
2 3%
Squamous Cell
Carcinoma &
Klebsiella
1 1%
PTB & CONS 1 1%
Mucormycosis 1 1%
Interstitial Pneumonitis 1 1%
Un diagnosed 4 6%
· PYOGENIC
BACTERIAL
INFECTION
38%
· TUBERCULOSIS
21%
· MUCORMYCOSI
S
2%
MALIGNANCY
26%
COMBINED
ETIOLOGY
6%
INTERSTITIAL
PNEUMONITIS
1% UNDIAGNOSED
6%
Fig 30:ETIOLOGY OF NRP
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BRONCHOALVEOLAR LAVAGE ANALYSIS:
BAL CYTOLOGY:
BAL fluid cytology revealed  malignancy  in 9%(n=6) of patients. In
remaining 91%  nonspecific inflammatory changes was observed.
BAL FLUID MICROBIOLOGICAL ANALYSIS:
 Out of 68 patients, in 28 patients BAL culture revealed bacterial
infection. Klebsiella pneumoniae was the predominant
organism[17%(n=12)] followed by Pseudomonas
aeruginosa(13%)(n=9).Klebsiella oxytoca was identified in 9%(n=6)
and Coagulase negative Staphylococcus aureus identified in 1%(n=1)
of patients.[Fig 32]
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INTERSTITIAL PNEUMONITIS
UN DIAGNOSED
Fig 31:over all etiology of NRP
No of Patients
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 Pyogenic bacterial infections was the most common etiology
observed with Klebsiella species ( 26%) being the predominant
pathogen.
Diagnosis of tuberculosis
 Tuberculosis was found as the etiology of non resolving pneumonia in 25%
(n=17) of patients.
 Out of this ,  AFB smear cytology was positive in 12 patients. BAL fluid
CBNAAT analysis detected Mycobacterium tuberculosis in 5 patients.
TBLB revealed caseating granulomas in 5 patients.
OTHER
DIAGNOSIS
59%KLEBSIELLA
PNEUMONIA
18%
PSEUDOMONAS
9%
KLEBSIELLA
OXYTOCA
13%
CONS
1%
Fig 32:BAL CULTURE RESULTS
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FOB guided protected specimen brush results:
FOB guided brush cytology revealed malignancy in 10 % (n=7) of
patients. Squamous cell carcinoma was the diagnosis in 4 patients and in
remaining patients brush cytology showed probable malignancy which was
confirmed later as squamous cell carcinoma by TBLB HPE reports.
TBLB  results:
Out of 68 patients, TBLB was done in 36 patients. Out of which,
TBLB diagnosed etiology of NRP in 24 patients. Malignancy was diagnosed
in 17 patients. Granulomatous  pathology was diagnosed in 5 patients. one
case HPE report revealed Mucormycosis infection and another one
diagnosed as Interstitial Pneumonitis.[Fig 33]
TABLE 5:Transbronchial lung Biopsy Results.
TBLB  RESULTS No of Patients
(n=24)
Percentage
Squamous cell
carcinoma
12 50%
Adeno carcinoma 4 17%
Small cell carcinoma 1 4%
Caseating granuloma 5 21%
Mucormycosis 1 4%
Interstitial
pneumonitis
1 4%
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CO MORBID CONDITIONS:
In my study,out of 68 patients,41.1%(n=28) patients were diabetic
and 51.47% were smokers. Diabetes is predominantly associated with
infectious etiology. Other comorbidites  were  CKD (n=8),post renal
transplant (n=1) and CA esophagus(n=1).Apart from this, COPD,CAD,OLD
CVA,Hypertension  were other co morbidities.[Fig 34]
0
2
4
6
8
10
12
No
 of
 Pa
tie
nts
Fig 33:TBLB RESULTS
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COMPLICATIONS:
Following FOB, chest X ray was taken in all patients. None of them
had  complications like pneumothorax. Only minor complications like
transient fever,   minor bleeding, transient  desaturation during the procedure
were noticed.There was no other major complications like massive
hemoptysis .
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DISCUSSION
The present study included 68 patients with non resolving
pneumonia. All patients were subjected to Bronchoscopy .Out of 68 ,
etiological diagnosis was made in 64 patients. USG Guided FNAC was done
in   remaining 4 Patients and diagnosis was made in 3 patients. However, no
etiology could be determined  in one patient.
Diagnostic yield of  FOB to determine the etiology of NRP  in my study
was 96%(n=64)which is comparable to other studies. In the  study  done by
Chaudhri et al(49), yield of FOB in NRP was 85.7% in the study done by
Bhupendra Kumar Jain et al(48) ,diagnostic yield of  FOB was 81%. Batau
Bhadke et al(51), concluded  FOB was diagnostic in 75% of NRP cases. In
study conducted by Asari et al(54),  the diagnostic yield of FOB  was 87% in
NRP. Nimit V Khara et al(53), studied diagnostic yield of FOB in 3 common
lung conditions(pneumonia,TB and lung cancer) and concluded  overall
yield of  FOB was 55.7% .
TABLE 6 :YIELD OF FOB IN NRP- COMPARISON OF STUDIES
Yield of FOB in NRP
My study 96%
Chaudhri et al 85.7%
Bhupendra kumar jain et al 81%
Batau bhadke et al 75%
75
In my study majority of the patients were males (80%).Among
females,  infections (71%) were the most common cause of etiology of NRP
when compared to malignancy (28%).Among  males ,the  major  cause of
NRP was infections, but incidence of malignancy was higher in males when
compared to females probably because of high incidence of smoking habit .
Depressed  muco ciliary function in smokers is also a risk factor to develop
infectious pneumonia.
In my study majority of patients were above 50 years of age. The reason
was depressed immunity and associated co morbidities more among them
when compared to young population.
In CT  chest findings, Right lung  involvement was more common
compared to left side. Right lower lobe (33%) was  predominantly involved
followed by right upper lobe(26%)and left lower lobe whereas in  studies
done by Chaudhri et al(49),Bhupendra Kumar Jain et al(48),Mohammed et al
(47)
,  right upper lobe involvement was more common.
Muco purulent secretions(32%) was noted in majority of
patients during gross inspection of tracheo bronchial tree. Around 25% of
patients showed no significant findings during gross inspection, but various
FOB guided procedure revealed  specific diagnosis in them.
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Most common etiology of NRP in my study was Pyogenic bacterial
infection (38%) followed by malignancy(26%) and
Tuberculosis(21%),which is comparable to other studies. Studies  conducted
by Mohammed El Shabrawy et al(47) , Batau Bhadke et al(51) , Chaudhri et
al(49) ,and  Amit J Asari et al(54),  concluded pyogenic bacterial infection was
the most common etiology of NRP followed by malignancy and  tuberculosis
.[Fig 35]
Fig 35:ETIOLOGY OF NRP IN VARIOUS STUDIES
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In contrast ,  study done by Jayaprakash et al(50) concluded, TB  was
the most common etiology followed by malignancy. In Visakhapatnam,
Vipparthi Surya Kumari et al(52) ,also concluded  similar results .[Fig 36]
Fig 36: ETIOLOGY OF NRP IN VARIOUS  STUDIES
Among the bacterial infections , Klebsiella  species was most common
cause followed by Pseudomonas and CONS  which is comparable to other
studies. Study done by  Mohammed El Shabrawy et al(47), revealed
Klebsiella pneumoniae was the most common organism isolated in 29
(24.8%) patients followed by Pseudomonas (19.65%) and Streptococcus
pneumoniae (19.65%).Vipparthi Surya Kumari et al(52) ,concluded in his
study, most common pathogen identified was Klebsiella (57.14%) followed
by Pseudomonas (28.5%) and E.coli (14.2%)
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Chaudhri et al(49) , reported Klebsiella species were isolated in 13 cases
followed by Peudomonas. All the above quoted studies showed Gram
negative organisms were the  predominant cause of non resolving
pneumonia when compared to gram positive organisms.
But, study conducted by Amit J Asari et al(54), found ,most frequent
organism isolated was streptococcus pneumoniae  (42.1%) and Batau
Bhadke et al(51), also found in his study that Streptococcus pneumoniae was
the most bacterial etiology found in 16(50%)patients followed by
Staphylococcus in  10(31.25%) and Klebsiella in 6 (18.75%) patients.
Bhupendra Kumar Jain et al(48) , concluded in his study , Streptococcus
pneumoniae (50%)was the most common bacteria isolated. when compared
to present study, All these studies showed gram positive organisms was
responsible in the etiology of non resolving pneumonia. The reason might
be due to variation of organisms according to their local epidemiological
pattern.
In the study done by Kyle R Brownback et al(56), in
immunocompromised individuals, viral infections were the most common
etiology  found in 38(48.1%)patients followed by bacterial in
9(11%),invasive Aspergillosis in 14(17.7%) and Pneumocystis jiroveci in 6
(7.6%) patients. In the immunocompromised individual the infectious causes
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were different from general population as they acquired more atypical
organisms and invasive fungal infections because of decreased immunity.
In the study done by Bhupendra Kumar Jain et al (48), Squamous cell variety
was the predominant carcinoma  which is comparable  to my study.
Arunabha D Chaudhri et al(49), also concluded in his study  that most
common cause  Squamous cell carcinoma  followed by adenocarcinoma .
In contrast, Jayaprakash et al(50), found Adenocarcinoma (42.1%) was the
most common among malignancies .Amit J Asari et al (54), reported
adenocarcinoma 4 (50%)was more common, followed by squamous cell
carcinoma 25%,small cell 12.5% and large cell carcinoma.. In both studies,
CT guided FNAC was used as one of the diagnostic procedures which is
better in diagnosing peripheral tumours like Adenocarcinoma. Squamous
cell carcinoma being a predominant central  tumour is better diagnosed by
FOB.
In all patients, before  the procedure  3 sputum samples were sent
for AFB smear to rule out smear positive tuberculosis. Using  FOB related
procedures tuberculosis was diagnosed in 17 patients with NRP in my study.
We utilised AFB smear, rapid diagnostic method CBNAAT and in few
patients TBLB to detect Mycobacterium tuberculosis. Use of FOB in
diagnosis of sputum smear negative pulmonary TB done by Novin
Nikbakshi  et al(55) found  tuberculosis in 63% of cases. .
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So FOB is a very  useful procedure  to diagnose TB in  smear negative
pulmonary tuberculosis patients. Combined  etiology was found in 4 patients
.Squamous cell  carcinoma associated with secondary bacterial
(Klebsiella)infection was found in one patient. In 2 patients, squamous cell
carcinoma was associated with tuberculosis.
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SUMMARY
The present study was conducted in department of Tuberculosis &
Respiratory Medicine , Tirunelveli medical college  which included 68
patients with non resolving pneumonia.  All patients were subjected to
Flexible fibreoptic  Bronchoscopy .Out of 68 patients , etiological diagnosis
was made in 94% of patients. Majority of the patients were males  and were
above 50 years of age. Majority of the patients with non resolving
pneumonia had lesions affecting Right lower lobe. Inflamed mucosa along
with mucopurulent secretions was noted in majority of patients during gross
inspection of tracheobronchial tree.
The  overall   diagnostic  yield of FOB in my study was 94%(n=64).
Infections(60%) were the most common cause of non resolving pneumonia
followed by malignancy(26.47%) in my study .Combined etiology was
noted in 6% and interstitial pneumonitis was diagnosed in 1% patients.
Among the infective causes, Gram negative bacterial infection was
predominantly diagnosed  in 38% of patients followed by Tuberculosis
(21%) and fungal infection - Mucormycosis in 2% of patients .
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Klebsiella species is the predominant bacterial infection identified followed
by Pseudomonas infection. Among  malignancies, Squamous cell variety is
the predominant type followed by Adenocarcinoma and small cell
carcinoma.
BAL fluid cytology revealed  malignancy  in 9%(n=6) of patients.
FOB guided Brush cytology revealed malignancy in 10 % (n=7) of patients.
TBLB diagnosed etiology of NRP in 68% (n=24 / 35) patients.
In my study, out of 68 patients,41.1% patients were diabetic and
51.47% were found to be smokers. Diabetes is predominantly associated
with infectious etiology.No major complications were encountered during
FOB in my study.Thus FOB is a useful diagnostic tool in evaluation of
patients with non resolving pneumonia.
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CONCLUSION
1.Bronchoscopy have a definitive role (Yield 94%) in the diagnosis of
Nonresolving pneumonia.
2.Infectious etiology including tuberculosis(60%) is the most common cause
of non resolving pneumonia.
3.Transbronchial lung biopsy(68%) may be recommended for all cases of
non resolving pneumonia to rule out malignancy .
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ANNEXURES
NAME: AGE: SEX: M/F I.P.NO:
OCCUPATION: D.O.A: D.O.D
C/O: H/O
INVESTIGATIONS:
CBC RFT LFT EL.,
TC DC PCV HB RBC ESR PLT U C
1. ICTC : PLEURAL FLUID :
2. SPUTUM AFB :
3. C & S : HBSAG, HCV :
1. PRIOR ATT
CAT  I CAT   II
2. DIABETIC
OHA
3. SMOKER
Beedi Cigar Duration
4. ALLERGY
5. COUGH
6. SPUTUM
Mucoid Purulent Blood
7. FEVER
LOW High
8. DYSPNEA
9. CHEST PAIN
10. LOW LOA
11. OTHER . S
4. FNAC : CT CHEST :
5. BIOPSY :
6. CHEST X-RAY
GIVEN TREATMENT:
1. ANTIBIOTICW
IV / ORAL
DURATION
2. OTHER TREATMENT S
FOR Findings:
DATE :
RESULTS :
1. BRONICHIAL WASH / BAL
 CELLCOUNT :
 CYTOLOGY :
 CULTURE SENSITIVITY :
 GRAM STAIN :
 AFB SMEAR :
2. BRONCHIAL BRUSH :
3. TBLB :
4. TBNA :
5. POST FOB SPUTUM AFB :
6. POST FOB CHEST X-RAY :
FINAL DIAGNOSIS:
REMARKS:
Xg;Gjy; gbtk;
vdJ EiuaPuypy; rsp NrHe;J ,Ug;gij kUj;Jfs; %yk;
mwpe;Jnfhz;Nld;. Mjd; fhuzj;ij fz;lwpa EiuaPuy; cs;Nehf;F
fUtpapd; (Bronchoscopy) %ykhf rsp vLj;J ghpNrhjid nra;a
mwpTWj;jg;gl;lJ. mg;ghpNrhjid nra;Ak; nghOJ. %r;R jpzwNyh> ,uj;j
frpNth. EiuaPuy; Rw;wp fhw;W NruNth tha;g;G cs;sJ vd;gij kUj;JtH
tpsf;fpdhH. ,Ug;gpDk; Nehapd; jd;ikia mwpa kUj;JtH Nkw;nfhs;Sk;
,g;ghpNrhjidf;F KO kzJld; rk;kjpf;fpNwd;. ,jd;%yk; Vw;gLk;
tpisTf;F kUj;JtNuh> kUj;Jt epHthfNkh nghWg;ghfhJ vd;gij
Vw;Wf;nfhs;fpNwd;.
ehs; : ,g;gbf;F
,lk;:
(Nehahsp / cwtpdhpd; ifnahg;gk;)
1 BALASUBRAMANIYAN 40 M
RT 
LOWERLOBE
NARROW
&IIREGUL
AR 
LUMEN
INFLAMMATORY NEGATIVE NEGATIVE NA POSITIVE NA NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY NO NO YES NO NO
2 PALANIAMMAL 50 F
LT LOWER 
LOBE
MASS INFLAMMATORY NEGATIVE NEGATIVE NA NEGATIVE POSITIVE NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY NO NO NO NO NO
3 PITCHAIKANNU 62  M  
 RT 
LOWERLOBE
MUCOID INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NEGATIVE NEGATIVEA KLEBSIELLA INFECTIVE NO NO NO
CA 
ESOPHAGU
S
YES
4 THIRUNAVUKARASU 52 M
LT LOWER 
LOBE
MUCOPU
RULENT
INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NEGATIVE NEGATIVEA KLEBSIELLA INFECTIVE NO YES YES NO NO
5 CHELLADURAI 50 M
RT UPPER 
LOBE
NORMAL INFLAMMATORY PSEUDOMANAS NEGATIVE NA NEGATIVE NA NEGATIVEA
PSEUDOMONAS 
AERUGINOSA
INFECTIVE YES NO NO COPD NO
6 AMARAVATHY 67 F
RT 
LOWERLOBE
MUCOPU
RULENT
INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE NO YES NO CKD YES
7 MAHESH 31 M
LT LOWER 
LOBE
MUCOPU
RULENT
INFLAMMATORY PSEUDOMANAS NEGATIVE NA NEGATIVE NA NEGATIVEA
PSEUDOMONAS 
AERUGINOSA
INFECTIVE NO NO YES NO NO
8 PANDARAM 75 M
RT MIDDLE 
LOBE
MUCOPU
RULENT
INFLAMMATORY PSEUDOMANAS NEGATIVE NA NEGATIVE NA NEGATIVEA
PSEUDOMONAS 
AERUGINOSA
INFECTIVE NO NO NO NO NO
9 AMUDHA 14 F
LT LOWER 
LOBE
MUCOPU
RULENT
INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE NO YES NO NO NO
10 IMMANUVEL JAMES 62 M
RT 
LOWERLOBE
NORMAL INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NEGATIVE NEGATIVEA KLEBSIELLA INFECTIVE NO NO YES COPD YES
11 GANAPATHY 49 M
RT UPPER 
LOBE
MUCOPU
RULENT
INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE YES NO YES
POST 
RENAL 
TRANSPLA
NT
NO
12 PERATCHI 52 M
RT 
LOWERLOBE
NORMAL INFLAMMATORY NEGATIVE POSITIVE NA NEGATIVE POSITIVE NEGATIVEA PTB INFECTIVE NO NO YES
B/L 
PLEURAL 
EFFUSION
NO
13 ALWAR 40 M
RT UPPER 
LOBE
NORMAL INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE YES YES YES CKD YES
14 MADASAMY 52 M
RT 
LOWERLOBE
MUCOPU
RULENT
INFLAMMATORY PSEUDOMANAS NEGATIVE NA NEGATIVE NA NEGATIVEA
PSEUDOMONAS 
AERUGINOSA
INFECTIVE YES YES NO NO YES
15 ANTONYSAMY 72 M
LT UPPER 
LOBE
MASS INFLAMMATORY NEGATIVE NEGATIVE NA NEGATIVE POSITIVE NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY NO NO YES COPD YES
16 PARAMASIVAN 54 M
RT 
LOWERLOBE
MASS INFLAMMATORY NEGATIVE NEGATIVE NA POSITIVE NA NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY NO YES YES COPD NO
17 VIKADASUDALAI 70 M
LT UPPER 
LOBE
NARROW
&IIREGUL
AR 
LUMEN
MALIGANACY NEGATIVE NEGATIVE NA NEGATIVE POSITIVE NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY NO NO YES COPD YES
18 PAULRAJ 67 M
RT 
LOWERLOBE
MUCOPU
RULENT
INFLAMMATORY NEGATIVE NEGATIVE NA NEGATIVE NEGATIVE NEGATIVEPOSITIVE
ADENO 
CARCINOMA
NO T 
DIAGNOSED
NO YES YES CAD YES
19 UDAIYAR 70 M
RT 
LOWERLOBE
NORMAL INFLAMMATORY NEGATIVE NEGATIVE NA NEGATIVE NEGATIVE NEGATIVEPOSITIVE
ADENO 
CARCINOMA
NO T 
DIAGNOSED
NO NO YES NO NO
20 ARUMUGANAINAR 50 M
RT 
LOWERLOBE
MUCOPU
RULENT
INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NEGATIVE NEGATIVEA KLEBSIELLA INFECTIVE NO NO NO NO NO
21 SUDALIMUTHU 61 M
RT UPPER 
LOBE
MASS INFLAMMATORY NEGATIVE POSITIVE NA NEGATIVE POSITIVE NEGATIVEA
PTB&SQUAMOUS 
CELL CARCINOMA
COMBINED 
ETIOLOGY
NO YES YES NO YES
22 PONROSI 16 F
MULTI 
LOBAR
MASS INFLAMMATORY NEGATIVE POSITIVE NA NEGATIVE POSITIVE NEGATIVEA PTB INFECTIVE NO NO NO NO NO
SL.N
O.
OTHER 
COMORBI
D  
CONDITIO
SMOKERDIABETIC
PRIOR 
ATT
USG 
GUIDED 
FNAC
ETIOLOGY
FINAL 
DIAGNOSIS
HYPER
TENSIO
N
AFB 
SMEAR
CBNAAT BRUSH TBLB FOB CYTOLOGY BAL CULTURENAME AGE SEX CT CHEST
SL.N
O.
OTHER 
COMORBI
D  
CONDITIO
SMOKERDIABETIC
PRIOR 
ATT
USG 
GUIDED 
FNAC
ETIOLOGY
FINAL 
DIAGNOSIS
HYPER
TENSIO
N
AFB 
SMEAR
CBNAAT BRUSH TBLB FOB CYTOLOGY BAL CULTURENAME AGE SEX CT CHEST
23 KRISHNAVENI 48 F
RT 
LOWERLOBE
NARROW
&IIREGUL
AR 
LUMEN
INFLAMMATORY NEGATIVE POSITIVE NA NEGATIVE POSITIVE NEGATIVEA
PTB&SQUAMOUS 
CELL CARCINOMA
COMBINED 
ETIOLOGY
NO NO NO NO NO
24 PITCHUMANI 58 M
RT UPPER 
LOBE
NORMAL INFLAMMATORY NEGATIVE POSITIVE NA NEGATIVE NA NEGATIVEA PTB INFECTIVE YES NO YES CKD YES
25 KRISHNAMMAL 62 F
LT UPPER 
LOBE
NARROW
&IIREGUL
AR 
LUMEN
INFLAMMATORY NEGATIVE POSITIVE NA NEGATIVE NA NEGATIVEA PTB INFECTIVE NO YES NO CAD YES
26 PETCHAMMAL 40 F
LT UPPER 
LOBE
MUCOID INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE NO NO NO NO NO
27 SUYUMBULINGAM 61 M
RT UPPER 
LOBE
NARROW
&IIREGUL
AR 
LUMEN
INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE POSITIVE NEGATIVEA
SQUAMOUS CELL 
CARCINOMA 
&KLEBSIELLA
COMBINED 
ETIOLOGY
NO NO YES COPD NO
28 SHAHUL HAMEED 39 M
RT UPPER 
LOBE
MASS INFLAMMATORY NEGATIVE NEGATIVE NA POSITIVE NA NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY YES YES NO NO NO
29 SUNDARAJAN 65 M LINGULAR
MUCOPU
RULENT
INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE NO YES YES CAD YES
30 DESING 54 M
RT UPPER 
LOBE
MASS INFLAMMATORY NEGATIVE NEGATIVE NA POSITIVE NA NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY NO NO YES COPD NO
31 MANI 55 M LINGULAR
MUCOPU
RULENT
INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE NO YES NO NO NO
32 MURUGAN 40 M
RT 
LOWERLOBE
MASS INFLAMMATORY NEGATIVE NEGATIVE NA POSITIVE POSITIVE NEGATIVEA
SMALL CELL 
CARCINOMA
MALIGNANCY NO NO YES NO NO
33 SHENBEGARAJ 30 M
LT LOWER 
LOBE
MASS INFLAMMATORY NEGATIVE NEGATIVE NA NEGATIVE POSITIVE NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY NO YES YES NO NO
34 MUTHUESAKKI 45 M
RT MIDDLE 
LOBE
NORMAL INFLAMMATORY CONS POSITIVE NA NEGATIVE NA NEGATIVEA PTB &CONS
COMBINED 
ETIOLOGY
YES YES YES CKD YES
35 MURUGAN 37 M
RT MIDDLE 
LOBE
NORMAL INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE NO NO YES NO NO
36 ANNAMALAI 58 M
RT UPPER 
LOBE
MUCOPU
RULENT
INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE NO YES NO CKD YES
37 PARAMASIVAN 34 M
LT UPPER 
LOBE
NORMAL INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE NO NO NO NO NO
38 PETCHAMMAL 68 F
RT 
LOWERLOBE
NARROW
&IIREGUL
AR 
LUMEN
INFLAMMATORY PSEUDOMANAS NEGATIVE NA NEGATIVE NA NEGATIVEA
PSEUDOMONAS 
AERUGINOSA
INFECTIVE NO NO NO NO NO
39 ARUMUGAM 65 M
LT LOWER 
LOBE
MUCOPU
RULENT
INFLAMMATORY PSEUDOMANAS NEGATIVE NA NEGATIVE NA NEGATIVEA
PSEUDOMONAS 
AERUGINOSA
INFECTIVE YES YES NO NO NO
40 ALAGAMMAL 60 F
RT UPPER 
LOBE
NARROW
&IIREGUL
AR 
LUMEN
INFLAMMATORY NEGATIVE NEGATIVE NA NEGATIVE POSITIVE NEGATIVEA
ADENO 
CARCINOMA
MALIGNANCY NO YES NO NO NO
41 SOKKALINGAM 70 M
RT 
LOWERLOBE
NORMAL INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE NO NO YES NO NO
42 SEENIPANDI 65 M
RT 
LOWERLOBE
MASS MALIGANACY NEGATIVE NEGATIVE NA POSITIVE POSITIVE NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY YES NO NO NO NO
43 KALIMUTHU 30 M
RT 
LOWERLOBE
MUCOPU
RULENT
INFLAMMATORY  NEGATIVE NA NEGATIVE NEGATIVE NEGATIVEA KLEBSIELLA INFECTIVE NO YES NO NO NO
44 AVUDAYAPPAN 61 M
RT UPPER 
LOBE
NARROW
&IIREGUL
AR 
LUMEN
MALIGANACY NEGATIVE NEGATIVE NA NEGATIVE POSITIVE NEGATIVEA
ADENO 
CARCINOMA
MALIGNANCY NO NO YES COPD NO
45 RAJASEKAR 50 M
RT MIDDLE 
LOBE
MUCOPU
RULENT
MALIGANACY NEGATIVE NEGATIVE NA NEGATIVE POSITIVE NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY NO NO YES COPD NO
46 KARUNAKARAN 70 M
RT UPPER 
LOBE
MUCOPU
RULENT
INFLAMMATORY PSEUDOMANAS NEGATIVE NA NEGATIVE NA NEGATIVEA
PSEUDOMONAS 
AERUGINOSA
INFECTIVE YES YES YES COPD YES
SL.N
O.
OTHER 
COMORBI
D  
CONDITIO
SMOKERDIABETIC
PRIOR 
ATT
USG 
GUIDED 
FNAC
ETIOLOGY
FINAL 
DIAGNOSIS
HYPER
TENSIO
N
AFB 
SMEAR
CBNAAT BRUSH TBLB FOB CYTOLOGY BAL CULTURENAME AGE SEX CT CHEST
47 SHENBEGARAJ 48 M
LT LOWER 
LOBE
NORMAL INFLAMMATORY KLEBSIELLA NEGATIVE NA NEGATIVE NA NEGATIVEA KLEBSIELLA INFECTIVE NO YES NO NO NO
48 ERUTHIYARAJ 79 M
RT UPPER 
LOBE
MUCOID INFLAMMATORY NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NEGATIVEA MUCORMYCOSIS INFECTIVE NO NO NO NO NO
49 GURUSAMY 70 M
LT LOWER 
LOBE
MUCOPU
RULENT
INFLAMMATORY PSEUDOMANAS NEGATIVE NA NEGATIVE NA NEGATIVEA
PSEUDOMONAS 
AERUGINOSA
INFECTIVE YES YES NO NO NO
50 MUTHUKRISHNAN 66 M
MULTI 
LOBAR
MUCOPU
RULENT
INFLAMMATORY NEGATIVE NEGATIVE POSITIVE NEGATIVE NA NEGATIVEA PTB INFECTIVE NO YES YES OLD CVA NO
51 ANTONYSAMY 47 M
RT 
LOWERLOBE
NORMAL INFLAMMATORY NEGATIVE POSITIVE NA NEGATIVE NA NEGATIVEA PTB INFECTIVE NO YES YES CKD YES
52 JEYAPAUL 52 M
RT UPPER 
LOBE
MUCOPU
RULENT
INFLAMMATORY NEGATIVE POSITIVE NA NEGATIVE NA NEGATIVEA PTB INFECTIVE NO YES YES
RT 
ISOMERIS
M
NO
53 CHELLAYA ASARI 75 M
RT 
LOWERLOBE
MASS INFLAMMATORY NEGATIVE NEGATIVE NEGATIVE POSITIVE POSITIVE NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY NO YES YES
CORPULM
ONALE
NO
54 CHELLAPANDI 51 M
LT UPPER 
LOBE
MASS MALIGANACY NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY NO YES YES CKD YES
55 PERIYASAMY 53 M
LT LOWER 
LOBE
NORMAL MALIGANACY NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NEGATIVEA
SQUAMOUS CELL 
CARCINOMA
MALIGNANCY NO NO NO NO NO
56 SHANMUGAVEL 70 M
RT UPPER 
LOBE
MUCOID INFLAMMATORY NEGATIVE NEGATIVE NA NEGATIVE POSITIVE NEGATIVEA PTB INFECTIVE NO NO YES CKD YES
57 PETCHI 60 M
RT 
LOWERLOBE
NORMAL INFLAMMATORY NEGATIVE NEGATIVE NA NEGATIVE POSITIVE NEGATIVEA
ADENO 
CARCINOMA
MALIGNANCY NO YES YES COPD YES
58 RAMASAMY 65 M
LT UPPER 
LOBE
NORMAL INFLAMMATORY NEGATIVE POSITIVE NA NEGATIVE NA NEGATIVEA PTB INFECTIVE YES YES YES NO NO
59 JEYAPAUL 47 M
RT UPPER 
LOBE
MUCOPU
RULENT
INFLAMMATORY NEGATIVE POSITIVE NA NEGATIVE NA NEGATIVEA PTB INFECTIVE NO NO YES NO NO
60 KALYANA SUNDARAM 60 M
MULTI 
LOBAR
NORMAL INFLAMMATORY NEGATIVE NEGATIVE NA NEGATIVE POSITIVE NEGATIVEA
INTERSTITIAL 
PNEUMONITIS
INTERSTIAL 
PNEUMONITIS
YES NO YES
CORPULM
ONALE
NO
61 VEL 40 M
RT 
LOWERLOBE
MUCOID INFLAMMATORY PSEUDOMANAS NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVEA
PSEUDOMONAS 
AERUGINOSA
INFECTIVE YES NO NO NO NO
62 VASANTHA 35 F
RT UPPER 
LOBE
MUCOID INFLAMMATORY NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVEA PTB INFECTIVE NO NO NO NO NO
63 RAMAN 50 M
LT LOWER 
LOBE
MUCOID INFLAMMATORY NEGATIVE NEGATIVE NA NEGATIVE NEGATIVE NEGATIVEPOSITIVE
ADENO 
CARCINOMA
NO T 
DIAGNOSED
YES NO NO COPD YES
64 MUTHIAH 65 M
RT 
LOWERLOBE
MUCOPU
RULENT
INFLAMMATORY NEGATIVE NEGATIVE POSITIVE NEGATIVE NEGATIVE NEGATIVEA PTB INFECTIVE NO NO NO NO NO
65 LEELAVATHY 56 F
RT UPPER 
LOBE
MASS INFLAMMATORY NEGATIVE NEGATIVE NEGATIVE NEGATIVE POSITIVE NEGATIVEA
ADENO 
CARCINOMA
MALIGNANCY NO NO NO NO NO
66 SUBBAMAL 52 F
RT 
LOWERLOBE
MUCOPU
RULENT
INFLAMMATORY NEGATIVE POSITIVE POSITIVE NEGATIVE POSITIVE NA PTB INFECTIVE NO NO NO
BRONCHIE
CTASIS
NO
67 ESWARI 48 F
LT UPPER 
LOBE
NORMAL INFLAMMATORY NEGATIVE NEGATIVE POSITIVE NEGATIVE POSITIVE NA PTB INFECTIVE NO NO NO NO NO
68 KALAVATHY 55 F
RT 
LOWERLOBE
MUCOID INFLAMMATORY NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVE NEGATIVEA NO DIAGNOSIS
NO T 
DIAGNOSED
NO NO NO NO NO
